DK2376536T3 - Midler mod pemphigus, som indeholder antistoffer mod fas-liganden - Google Patents
Midler mod pemphigus, som indeholder antistoffer mod fas-liganden Download PDFInfo
- Publication number
- DK2376536T3 DK2376536T3 DK09801201.6T DK09801201T DK2376536T3 DK 2376536 T3 DK2376536 T3 DK 2376536T3 DK 09801201 T DK09801201 T DK 09801201T DK 2376536 T3 DK2376536 T3 DK 2376536T3
- Authority
- DK
- Denmark
- Prior art keywords
- fasl
- tyr
- ser
- antibody
- pemphigus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (6)
1. Forbindelse valgt blandt: (i) et monoklonalt humant antistof eller et antigenbindende fragment deraf, som er specifikt for humant Fas-ligandprotein (FasL), hvor det monoklonale antistof omfatter mindst én variabel tungkæde-region og mindst én variabel letkæ-de-region, hvor aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR, complementary determining regions) i den tunge kæde er: am m: Arp His 8# Tf*r I« SO Hø: 13}eller (to) GØR H1 r Ser His Oly Is $«r ($£Q tO RØ; 14), QtM H2: Trp 1# Asm Als Tyr Asn Oly Am Ihr Am Tyr Als Gin tys Vsl Øls Gfy (SEØ 10 HD; 1$) eller 15¾) 000 Hit Ifp is ΑΙ» Tyr Ser Oly Asn TPr Asn Tyr Ais Gtn tys teu m% Gly CSEQ 10 Hø: 16)* |5s| ØØR H3: Glu TPr Rist Ve! Arp øfy Vs! Prs Lmi A$p Tyr (SEølOHø: 17) eller cm H3: OlM TAr Met Vs! Arp Ofy Vs! Prs Cys Asp Tyr (SEQ 10 NO: 1ST og aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den lette kæde er f%) CDR il; Arp Als Os? øls Ssr Vat Ser Ser Ssr Tyr is« Als fSiø !D HD: 1% 11¾) CDR it: Gly Als Ser Sar Arg Als Tbr |Sm ID Hø; 28), C«s| COR13: Øn øls Tyr Oly Sar Ost Rra Trp TPr (Siø ID HØ: 21) og (ii) et antistof eller et antigenbindende fragment deraf, som genkender den samme epitop på humant FasL som et antistof med en variabel letkæde-region, der omfatter aminosyresekvensen yYGÅSS^TeiPORfegSGSGTDFTtTlSRtEPEDFmArYCSa^i og den variable tungkæde-region, der omfatter aminosyresekvensen cmtmBSÅE^KRPaåSWCWOlCASGYFIEliSEWVROåPmeiRW yBVV»MåYRtSNTMYAOBYQORWM?TORSTSTAYIIi:LR8iPI:^>PAA¥ eller OVaiYCBG^KICf^SVKYSOimSOWf^fflSWVRQ^PGaGLeW til anvendelse til forebyggelse og/eller behandling af pemphigus.
2. Forbindelse til anvendelsen ifølge krav 1, hvor forbindelsen er: (i) et monoklonalt humant antistof eller et antigenbindende fragment deraf, som er specifikt for humant Fas-ligandprotein (FasL), hvor det monoklonale antistof omfatter mindst én variabel tungkæde-region og mindst én variabel letkæ-de-region, hvor aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den tunge kæde er: fa,f CDR H1> Ail His Oly S§# Thr (SEG ID MG:: 13|* ø# 038 H£: Τφ 8» fim .Als Tyr fim Giy fim Th? fim Tyr Ab Ofrs lpVs! ofe GI? (SEQ 10 NO: IS), fca) CPR m Thr tm Val Af$ Off Var Pm Im Asp Tyr fSEG ID NO: 17}.. og aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den lette kæde er f%) CDR il: Ast) Ab S«? CVn Sar Val Sar Sar Sar Tyr Laa Als pSOIDNOifiT lis) ØOR tt: GI? Ala Sar Sar Arp Als Tfcr fSEQ 10 NO: W% COR U: Ola Ola Tyr Oly Sar Sar Rra Trp Thr C'SEO ID NO: 21) til anvendelse til forebyggelse og/eller behandling af pemphigus.
3. Forbindelse til anvendelsen ifølge krav 1, hvor forbindelsen er: (i) et monoklonalt humant antistof eller et antigenbindende fragment deraf, som er specifikt for humant Fas-ligandprotein (FasL), hvor det monoklonale antistof omfatter mindst én variabel tungkæde-region og mindst én variabel letkæ-de-region, hvor aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den tunge kæde er: (éé Om Hl: Ser His U (SEQ !S> NC& py €01¾ H2; Trp 1¾ A$r* Als Tyr §*f Ofy Mm Ihr tei Tyt te m lp Ui* Qiy iSSO ID NO; li), {CssJ OPR H3: GO Tøf Vii Arg Gly V*l Fro Cys Asp Tyr (SIO ID NO; IS), og aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den lette kæde er CDR LI: Arg Afe Ser Gift Ser Val Ser Ser Ser Tyr Im Mm mm ID NO; 10), fi&> CDR 12: Dly Als Ser Ser Arg Ala Thf |SEQ ID NO; 2D), |rs) DDR U; Oie Ole Tyt Oly Ser Ser Pro Trp Tøf (SIG 10 NO; 211 til anvendelse til forebyggelse og/eller behandling af pemphigus.
4. Forbindelse til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor antistoffet eller et antigenbindende fragment deraf er valgt blandt et delvist eller helt humaniseret antistof, et delvist eller helt humaniseret enkeltkædet antistof eller et fragment deraf.
5. Forbindelse til anvendelsen ifølge et hvilket som helst af de foregående krav, hvor forbindelsen anvendes i en kombinationsbehandling sammen med mindst én yderligere behandling, som er effektiv mod pemphigus.
6. Forbindelse til anvendelsen ifølge krav 5, hvor forbindelsen anvendes i kombination med mindst ét yderligere immunosuppressivt lægemiddel, navnlig med mindst ét yderligere steroid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2008/010597 WO2009074339A1 (en) | 2007-12-12 | 2008-12-12 | Remedies for pemphigus containing anti fas ligand antobodies |
| PCT/EP2009/067129 WO2010066914A2 (en) | 2008-12-12 | 2009-12-14 | Remedies for pemphigus containing anti fas ligand antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2376536T3 true DK2376536T3 (da) | 2015-06-08 |
Family
ID=42060995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09801201.6T DK2376536T3 (da) | 2008-12-12 | 2009-12-14 | Midler mod pemphigus, som indeholder antistoffer mod fas-liganden |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9255150B2 (da) |
| EP (1) | EP2376536B1 (da) |
| JP (1) | JP5773882B2 (da) |
| KR (1) | KR101769858B1 (da) |
| CN (1) | CN102405234A (da) |
| AU (1) | AU2009326978B2 (da) |
| BR (1) | BRPI0922201A2 (da) |
| CA (1) | CA2746334C (da) |
| DK (1) | DK2376536T3 (da) |
| ES (1) | ES2534799T3 (da) |
| HK (1) | HK1161884A1 (da) |
| IL (1) | IL213213A (da) |
| MX (1) | MX2011006203A (da) |
| NZ (1) | NZ593312A (da) |
| PL (1) | PL2376536T3 (da) |
| PT (1) | PT2376536E (da) |
| RU (1) | RU2556818C2 (da) |
| SI (1) | SI2376536T1 (da) |
| WO (1) | WO2010066914A2 (da) |
| ZA (1) | ZA201104130B (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015165973A1 (en) | 2014-04-29 | 2015-11-05 | Apogenix Gmbh | Diagnostic anti-cd95l antibody |
| EP3353208B1 (en) * | 2015-09-23 | 2024-08-07 | Apogenix AG | Anti-cd95l antibody |
| RU2613718C1 (ru) * | 2015-11-24 | 2017-03-21 | Федеральное государственное бюджетное учреждение "Государственный научный центр дерматовенерологии и косметологии" Минздрава России (ФГБУ ГНЦДК Минздрава России) | Способ моделирования пузырчатки у мышей методом введения иммуноглобулинов класса g |
| CN116888257A (zh) * | 2022-01-21 | 2023-10-13 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| WO2024200287A1 (en) * | 2023-03-24 | 2024-10-03 | Pincell S.R.L. | Anti-fas ligand (fasl) antibodies in the treatment of sjs/ten diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0872488B1 (en) | 1995-03-20 | 2006-05-24 | Ko Okumura | MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH Fas LIGAND AND PROCESS FOR PRODUCING THE SAME |
| CN1196733A (zh) | 1995-06-30 | 1998-10-21 | 持田制药株式会社 | 抗Fas配体抗体和利用抗Fas配体抗体的测定方法 |
| US6114507A (en) * | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
| AU725329B2 (en) | 1996-09-02 | 2000-10-12 | Ko Okumura | Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand |
| IL164011A0 (en) | 2002-03-21 | 2005-12-18 | Lilly Co Eli | Antagonistic anti-hfas ligand human antibodies andfragments thereof |
| ES2538489T3 (es) * | 2007-12-12 | 2015-06-22 | Pincell Srl | Remedios para pénfigo que contienen anticuerpos contra el ligando Fas |
| FR2933264B1 (fr) | 2008-06-25 | 2012-10-26 | Actimagine | Procede d'authentification d'un utilisateur d'un service sur terminal mobile. |
-
2009
- 2009-12-14 JP JP2011540140A patent/JP5773882B2/ja active Active
- 2009-12-14 EP EP09801201.6A patent/EP2376536B1/en active Active
- 2009-12-14 BR BRPI0922201A patent/BRPI0922201A2/pt not_active Application Discontinuation
- 2009-12-14 PL PL09801201T patent/PL2376536T3/pl unknown
- 2009-12-14 WO PCT/EP2009/067129 patent/WO2010066914A2/en active Application Filing
- 2009-12-14 CN CN2009801545173A patent/CN102405234A/zh active Pending
- 2009-12-14 MX MX2011006203A patent/MX2011006203A/es active IP Right Grant
- 2009-12-14 ES ES09801201.6T patent/ES2534799T3/es active Active
- 2009-12-14 PT PT98012016T patent/PT2376536E/pt unknown
- 2009-12-14 US US13/139,048 patent/US9255150B2/en active Active
- 2009-12-14 AU AU2009326978A patent/AU2009326978B2/en active Active
- 2009-12-14 KR KR1020117015680A patent/KR101769858B1/ko active IP Right Grant
- 2009-12-14 DK DK09801201.6T patent/DK2376536T3/da active
- 2009-12-14 SI SI200931159T patent/SI2376536T1/sl unknown
- 2009-12-14 NZ NZ593312A patent/NZ593312A/xx unknown
- 2009-12-14 RU RU2011128702/10A patent/RU2556818C2/ru active
- 2009-12-14 CA CA2746334A patent/CA2746334C/en active Active
-
2011
- 2011-05-30 IL IL213213A patent/IL213213A/en active IP Right Grant
- 2011-06-03 ZA ZA2011/04130A patent/ZA201104130B/en unknown
-
2012
- 2012-03-08 HK HK12102368.6A patent/HK1161884A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2534799T3 (es) | 2015-04-29 |
| AU2009326978B2 (en) | 2013-09-12 |
| IL213213A0 (en) | 2011-07-31 |
| JP2012511550A (ja) | 2012-05-24 |
| CN102405234A (zh) | 2012-04-04 |
| KR20110094327A (ko) | 2011-08-23 |
| RU2556818C2 (ru) | 2015-07-20 |
| SI2376536T1 (sl) | 2015-04-30 |
| PT2376536E (pt) | 2015-05-11 |
| US9255150B2 (en) | 2016-02-09 |
| EP2376536A2 (en) | 2011-10-19 |
| WO2010066914A2 (en) | 2010-06-17 |
| RU2011128702A (ru) | 2013-01-20 |
| IL213213A (en) | 2015-10-29 |
| EP2376536B1 (en) | 2015-02-25 |
| PL2376536T3 (pl) | 2015-10-30 |
| WO2010066914A3 (en) | 2010-09-02 |
| KR101769858B1 (ko) | 2017-08-21 |
| CA2746334C (en) | 2018-06-12 |
| ZA201104130B (en) | 2012-02-29 |
| BRPI0922201A2 (pt) | 2015-12-29 |
| MX2011006203A (es) | 2011-07-20 |
| CA2746334A1 (en) | 2010-06-17 |
| NZ593312A (en) | 2013-02-22 |
| US20110243946A1 (en) | 2011-10-06 |
| JP5773882B2 (ja) | 2015-09-02 |
| AU2009326978A1 (en) | 2011-07-07 |
| HK1161884A1 (en) | 2012-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2231708T3 (da) | Midler mod pemphigus, som indeholder antistoffer mod fas-liganden | |
| US9114131B2 (en) | Antibody targeting osteoclast-related protein Siglec-15 | |
| EP3170841A1 (en) | NOVEL ANTI-HUMAN Tie2 ANTIBODY | |
| DK2376536T3 (da) | Midler mod pemphigus, som indeholder antistoffer mod fas-liganden | |
| AU2011349124B2 (en) | Anti-P-selectin antibodies and methods of their use and identification | |
| EA041723B1 (ru) | Анти-c5 антитела и их применение |